Although it is difficult to draw any firm conclusions from these results due to the restricted number of samples tested from two small cohorts of patients included in this pilot study, they do show that it is indeed possible to quantify both the direct VEGF neutralizing activity of bevacizumab and the host mediated ADCC of activity bevacizumab in samples from patients with ovarian cancer or glioblastoma treated with bevacizumab and that clear differences are observed between samples from individual patients. This evidence concerns the gene VEGFA and ovarian carcinoma.